PD-L1 siRNA incorporation into a cationic liposomal tumor mRNA vaccine enhances cytotoxic T cell activation and prevents immune evasion
Source abstract
Abstract
T cells. Furthermore, cationic liposomes play dual roles as carriers crucial for preserving the integrity of nucleic acids for antigen translation and as inhibitors of autophagy-a process essential for both promoting antigen cross-presentation and revitalizing MHC-I expression on tumor cells, thereby increasing their immunogenicity. This cationic liposomal vaccine represents a promising strategy in cancer immunotherapy, launching a multidimensional offensive against tumor cells that enhances cytotoxic T lymphocyte (CTL) activation and prevents tumor immune evasion.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Immunotherapy and Immune Responses · RNA Interference and Gene Delivery · Cancer Immunotherapy and Biomarkers
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (79)
Show source-provided references
1. Development of effective tumor vaccine strategies based on immune response cascade reactions10.1002/adhm.202100299 ↗
2. Mechanisms of SARS-CoV-2 entry into cells10.1038/s41580-021-00418-x ↗
3. Structural biology of SARS-CoV-2 and implications for therapeutic development10.1038/s41579-021-00630-8 ↗
4. Lipid nanoparticle chemistry determines how nucleoside base modifications alter mRNA delivery10.1016/j.jconrel.2021.11.022 ↗
5. A single-dose mRNA vaccine provides a long-term protection for hACE2 transgenic mice from SARS-CoV-210.1038/s41467-021-21037-2 ↗
6. J. Liu, P. Budylowski, R. Samson, B.D. Griffin, G. Babuadze, B. Rathod, K. Colwill, J.A. Abioye, J.A. Schwartz, R. Law, L. Yip, S.K. Ahn, S. Chau, M. Naghibosadat, Y. Arita, Q. Hu, F.Y. Yue, A. Banerjee, W.R. Hardy, K. Mossman, S. Mubareka, R.A. Kozak, M.S. Pollanen, N. Martin Orozco, A.-C. Gingras, E.G. Marcusson, M.A. Ostrowski, Preclinical evaluation of a SARS-CoV-2 mRNA vaccine PTX-COVID19-B, Sci. Adv. 8 (n.d.) eabj9815. https://doi.org/10.1126/sciadv.abj9815.10.1126/sciadv.abj9815 ↗
7. The germinal centre B cell response to SARS-CoV-210.1038/s41577-021-00657-1 ↗
8. Advances in COVID-19 mRNA vaccine development10.1038/s41392-022-00950-y ↗
9. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA10.1016/j.immuni.2005.06.008 ↗
10. Novel cap analogs for in vitro synthesis of mRNAs with high translational efficiency10.1261/rna.7380904 ↗
11. Cancer gene mutation frequencies for the U.S. population10.1038/s41467-021-26213-y ↗
12. The challenge and prospect of mRNA therapeutics landscape10.1016/j.biotechadv.2020.107534 ↗
13. The blockade of immune checkpoints in cancer immunotherapy10.1038/nrc3239 ↗
14. Recent advances in mRNA-LNP therapeutics: immunological and pharmacological aspects10.1186/s12951-022-01478-7 ↗
15. Self-assembled mRNA vaccines10.1016/j.addr.2020.12.014 ↗
16. Optimizing cardiac delivery of modified mRNA10.1016/j.ymthe.2017.03.016 ↗
17. Lipid nanoparticles for mRNA delivery10.1038/s41578-021-00358-0 ↗
18. Melittin-lipid nanoparticles target to lymph nodes and elicit a systemic anti-tumor immune response10.1038/s41467-020-14906-9 ↗
19. Immunotherapy with allotumour mRNA-transfected dendritic cells in androgen-resistant prostate cancer patients10.1038/sj.bjc.6602761 ↗
20. Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma10.1007/s00262-013-1453-3 ↗
21. T cell activation10.1146/annurev.immunol.021908.132706 ↗
22. How the T cell repertoire becomes peptide and MHC specific10.1016/j.cell.2005.05.013 ↗
23. MYC regulates the antitumor immune response through CD47 and PD-L110.1126/science.aac9935 ↗
24. Recent advances in overcoming barriers to cell-based delivery systems for cancer immunotherapy
25. Kinetics and nadir of responses to immune checkpoint blockade by anti-PD1 in patients with classical Hodgkin lymphoma10.1016/j.ejca.2017.12.015 ↗
26. EGFR-specific PEGylated immunoliposomes for active siRNA delivery in hepatocellular carcinoma10.1016/j.biomaterials.2011.09.035 ↗
27. Inhibition of hepatocellular carcinoma growth using immunoliposomes for co-delivery of adriamycin and ribonucleotide reductase M2 siRNA10.1016/j.biomaterials.2013.08.088 ↗
28. Lipid nanoparticle (LNP) enables mRNA delivery for cancer therapy10.1002/adma.202303261 ↗
29. Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I10.1038/s41586-020-2229-5 ↗
30. Selectivity of mRNA degradation by autophagy in yeast10.1038/s41467-021-22574-6 ↗
31. Targeting RNA N6-methyladenosine to synergize with immune checkpoint therapy10.1186/s12943-023-01746-6 ↗
32. Autophagy modulation as a potential therapeutic target for diverse diseases10.1038/nrd3802 ↗
33. Targeting autophagy in cancer10.1038/nrc.2017.53 ↗
34. Cerebrospinal fluid efflux through dynamic paracellular pores on venules as a missing piece of the brain drainage system
35. EGFR-specific PEGylated immunoliposomes for active siRNA delivery in hepatocellular carcinoma10.1016/j.biomaterials.2011.09.035 ↗
36. An antibiotic-free platform for eliminating persistent Helicobacter pylori infection without disrupting gut microbiota10.1016/j.apsb.2024.03.014 ↗
37. X. Zhang, M. Zhang, H. Cui, T. Zhang, Z. Zhang, J. Li, J. Zhou, X. Jiang, C. Liu, J. Gao, Integrated Copper Nanomaterials-Decorated Microsphere Photothermal Platform for Comprehensive Melanoma Treatment, Small Structures n/a (n.d.) 2400028. https://doi.org/10.1002/sstr.202400028.10.1002/sstr.202400028 ↗
38. The protamine family of sperm nuclear proteins10.1186/gb-2007-8-9-227 ↗
39. Low molecular weight protamine (LMWP): a nontoxic protamine substitute and an effective cell-penetrating peptide10.1016/j.jconrel.2014.05.056 ↗
40. Nuclear matrix interactions at the human protamine domain: a working model of potentiation10.1074/jbc.M409415200 ↗
41. Protamine sulfate as an effective alternative to polybrene in retroviral-mediated gene-transfer: implications for human gene therapy10.1016/0166-0934(89)90132-8 ↗
42. Efficient colorectal cancer gene therapy with IL-15 mRNA nanoformulation10.1021/acs.molpharmaceut.0c00451 ↗
43. Targeted delivery of antisense oligodeoxynucleotide and small interference RNA into lung cancer cells10.1021/mp060039w ↗
44. Efficient oncogene silencing and metastasis inhibition via systemic delivery of siRNA10.1038/mt.2008.51 ↗
45. Immunotherapy of tumor RNA-loaded lipid nanoparticles against hepatocellular carcinoma10.2147/IJN.S291421 ↗
46. Lipid nanoparticle formulations for enhanced Co-delivery of siRNA and mRNA10.1021/acs.nanolett.8b01101 ↗
47. Autophagy-modulating biomembrane nanostructures: a robust anticancer weapon by modulating the inner and outer cancer environment10.1016/j.jconrel.2023.12.032 ↗
48. Autophagy inhibition enhances PD-L1 expression in gastric cancer10.1186/s13046-019-1148-5 ↗
49. Factor of time in dendritic cell (DC) maturation: short-term activation of DCs significantly improves type 1 cytokine production and T cell responses10.1186/s12967-024-05368-4 ↗
50. Two-step maturation of immature DCs with proinflammatory cytokine cocktail and poly(I:C) enhances migratory and T cell stimulatory capacity10.1016/j.vaccine.2010.01.061 ↗
51. Monocyte-derived DC maturation strategies and related pathways: a transcriptional view10.1007/s00262-010-0954-6 ↗
52. Nucleic acids as antigens10.1016/S0065-2776(08)60523-4 ↗
53. Pathogen recognition by innate immunity and its signaling10.2183/pjab.85.143 ↗
54. Mechanism and medical implications of mammalian autophagy10.1038/s41580-018-0003-4 ↗
55. Engineering chameleon prodrug nanovesicles to increase antigen presentation and inhibit PD-L1 expression for circumventing immune resistance of cancer10.1002/adma.202102668 ↗
56. Dendritic nanomedicine with boronate bonds for augmented chemo-immunotherapy via synergistic modulation of tumor immune microenvironment
57. Nanopurpurin-based photodynamic therapy destructs extracellular matrix against intractable tumor metastasis10.1016/j.biomaterials.2018.04.045 ↗
58. Reprogramming the immunosuppressive tumor microenvironment through nanomedicine: an immunometabolism perspective10.1016/j.ebiom.2024.105301 ↗
59. Immune checkpoint silencing using RNAi-incorporated nanoparticles enhances antitumor immunity and therapeutic efficacy compared with antibody-based approaches10.1136/jitc-2021-003928 ↗
60. siRNA nanoparticle targeting PD-L1 activates tumor immunity and abrogates pancreatic cancer growth in humanized preclinical model10.3390/cells10102734 ↗
61. PD-L1 siRNA hitched polyethyleneimine-elastase constituting nanovesicle induces tumor immunogenicity and PD-L1 silencing for synergistic antitumor immunotherapy10.1186/s12951-024-02700-4 ↗
62. ROS-sensitive PD-L1 siRNA cationic selenide nanogels for self-inhibition of autophagy and prevention of immune escape
63. Noncanonical splicing junctions between exons and transposable elements represent a source of immunogenic recurrent neo-antigens in patients with lung cancer10.1126/sciimmunol.abm6359 ↗
64. Microproteins encoded by noncanonical ORFs are a major source of tumor-specific antigens in a liver cancer patient meta-cohort10.1126/sciadv.adn3628 ↗
65. Enhancing CRISPR/Cas gene editing through modulating cellular mechanical properties for cancer therapy10.1038/s41565-022-01122-3 ↗
66. mRNA vaccine with antigen-specific checkpoint blockade induces an enhanced immune response against established melanoma10.1016/j.ymthe.2017.11.009 ↗
67. IL-20 antagonist suppresses PD-L1 expression and prolongs survival in pancreatic cancer models10.1038/s41467-020-18244-8 ↗
68. eEF2K promotes PD-L1 stabilization through inactivating GSK3β in melanoma10.1136/jitc-2021-004026 ↗
69. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single arm, phase 2 trial10.1016/S0140-6736(16)00561-4 ↗
70. PD-1 and its ligands in tolerance and immunity10.1146/annurev.immunol.26.021607.090331 ↗
71. The reversion of DNA methylation-induced miRNA silence via biomimetic nanoparticles-mediated gene delivery for efficient lung adenocarcinoma therapy10.1186/s12943-022-01651-4 ↗
72. A novel strategy inducing autophagic cell death in Burkitt's lymphoma cells with anti-CD19-targeted liposomal rapamycin10.1038/bcj.2014.2 ↗
73. Cationic liposomes promote antigen cross-presentation in dendritic cells by alkalizing the lysosomal pH and limiting the degradation of antigens10.2147/IJN.S125866 ↗
74. Tumor‐associated macrophage‐derived exosomal LINC01232 induces the immune escape in glioma by decreasing surface MHC‐I expression
75. Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer10.1038/nature22341 ↗
76. The relationship between autophagy and PD-L1 and their role in antitumor therapy10.3389/fimmu.2023.1093558 ↗
77. Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphoma10.1182/blood-2018-01-829424 ↗
78. Tuberculosis is associated with expansion of a motile, permissive and immunomodulatory CD16(+) monocyte population via the IL-10/STAT3 axis10.1038/cr.2015.123 ↗
79. Combination chemo-immunotherapy for pancreatic cancer using the immunogenic effects of an irinotecan silicasome nanocarrier plus anti-PD-1